Overactive bladder -: which diagnostic investigations are necessary before initiating primary treatment?

被引:0
|
作者
Schönberger, B [1 ]
机构
[1] Humboldt Univ, Univ Klinikum, Urol Klin, Berlin, Germany
来源
UROLOGE A | 2003年 / 42卷 / 06期
关键词
overactive bladder; idiopathic detrusor overactivity; urgency; urge incontinence;
D O I
10.1007/s00120-003-0362-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The symptom complex of frequency and urgency with or without urge incontinence is termed overactive bladder (OAB) according to the new definition by the International Continence Society. The background for this change in definition is the great economic and social importance of the disease, the rising costs in medicine, and the tendency to develop the simplest possible therapeutic strategies. Therapy consists of the administration of an anticholinergic/spasmolytic drug for at least 3 months. Although a great percentage of patients with OAB can be clinically identified the required exclusion of "local pathologic and metabolic factors" calls for a minimal diagnostic program to come to fairly exact findings. This includes a detailed case history with standardized and evaluated questionnaires, a bladder diary, detailed clinical examination, urine analysis consisting of microscopic and microbiologic examination, uroflowmetry including measurement of residual urine,and examination of the kidneys and upper urinary tract (determination of creatine. and sonography). Minimally invasive tests to, improve validity regarding obstruction and detrusor overactivity are being developed. These tests are intended to make an invasive pressure-flow study unnecessary. However, using the above-described minimal diagnostic program gram, one has to take into account that patients suffering from complaints without underlying idiopathic detrusor overactivity and with urgency/urge incontinence due to bladder outlet obstruction are referred for primary therapy with anticholinergic/antispastic drugs. In cases of neurologic signs, pathologic urinary findings, reduced urinary flow rate with residual urine, and problems of the upper urinary tract, further diagnostic studies are necessary. In any case, such patients need not undergo primary therapy on the basis of a clinical diagnosis. An ex iuvantibus therapy with anticholinergic drugs - even if limited to 3 months - is not acceptable if the diagnostic minimal program is not used.
引用
收藏
页码:787 / 792
页数:6
相关论文
共 46 条
  • [1] Overactive bladder-which treatment when?
    Pannek, J.
    UROLOGE, 2017, 56 (12): : 1532 - 1538
  • [3] Time Course of Treatment for Primary Enuresis With Overactive Bladder
    Im, Young Jae
    Lee, Jung Keun
    Park, Kwanjin
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2018, 22 (02) : 107 - 113
  • [4] Overactive Bladder: Treatment Options in Primary Care Medicine
    Sussman, David O.
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2007, 107 (09): : 379 - 385
  • [5] Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
    Hsiao, Sheng-Mou
    Liao, Chun-Hou
    Lin, Ho-Hsiung
    Kuo, Hann-Chorng
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2015, 19 (03) : 171 - 177
  • [6] Which beta-Adrenoceptor Subtypes are Important in the Treatment of Overactive Bladder?
    Yamanishi, Tomonori
    Kamai, Takao
    Sakakibara, Ryuji
    Uchiyama, Tomoyuki
    Yamamoto, Tatsuya
    Ito, Takashi
    Yoshida, Ken-ichiro
    CURRENT DRUG THERAPY, 2007, 2 (01) : 79 - 84
  • [7] The treatment of overactive bladder: A primary care provider’s perspective
    Matt T. Rosenberg
    Current Urology Reports, 2008, 9 (6)
  • [8] Primary care management of overactive bladder symptoms: evaluation and treatment
    Itam, Sarah
    Singh, Gurpreet
    BRITISH JOURNAL OF GENERAL PRACTICE, 2017, 67 (657): : 187 - 188
  • [9] Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary?
    Van der Pal, F
    Van Balken, MR
    Heesakkers, JPFA
    Debruyne, FMJ
    Bemelmans, BLH
    BJU INTERNATIONAL, 2006, 97 (03) : 547 - 550
  • [10] Überaktive Blase – wann welche Therapie?Overactive bladder—which treatment when?
    J. Pannek
    Der Urologe, 2017, 56 : 1532 - 1538